STAT

SEPTEMBER 15, 2024

Exact Sciences, which has for years sold a stool-based colon cancer test, on Monday announced that a blood-based test it’s developing showed promise in accurately detecting the disease. In a study of more than 3,000 samples, the company reported that its test detected 88.3% of cancers and correctly returned a negative result 90.1% of the time, test features known as sensitivity and specificity, respectively.

317

317

BioPharma Dive

SEPTEMBER 15, 2024

Final follow-up results suggest Opdivo and Yervoy could be close to a cure for some people with advanced melanoma, shifting how doctors administer follow-up care.

125

125

STAT

SEPTEMBER 15, 2024

BARCELONA, Spain — An AstraZeneca immunotherapy, given both before and after surgery, improved survival rates in patients with bladder cancer, results that could reshape how muscle-invasive bladder tumors are treated.  The regimen using Imfinzi, the company’s anti-PD-L1 checkpoint inhibitor, cut the risk of death by 25% compared to treating patients before surgery with chemotherapy alone, researchers reported Sunday.

Chemotherapy 312

Chemotherapy 312

pharmaphorum

SEPTEMBER 15, 2024

GSK, iTeos TIGIT drug belrestotug shows efficacy in PD-L1-high NSCLC trial at ESMO, giving some positive news for the beleaguered class

115

115

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Communication

STAT

SEPTEMBER 15, 2024

This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the European Society for Medical Oncology’s annual meeting in Barcelona, Spain. Sign up for the remaining editions  here. AZ hits in bladder cancer, as regulatory issue looms The applause mentioned above was for AstraZeneca’s Phase 3 NIAGARA study in bladder cancer, which showed that giving patients the checkpoint inhibitor Imfinzi — both before and after surgery — cut the risk of death by

287

287

pharmaphorum

SEPTEMBER 15, 2024

Women with HER2-positive breast cancer can be treated with AstraZeneca and Daiichi Sankyo's Enhertu, regardless of whether their cancer has spread to the brain, according to a new study.The results of the open-label DESTINY-Breast12 trial – reported at the ESMO cancer congress in Barcelona – showed that nearly two-thirds (61.6%) of patients with brain metastases at baseline who were treated with the HER2-directed antibody-drug conjugate (ADC) were alive without disease progression at one year.

Labelling 111

Labelling 111

Express Pharma

SEPTEMBER 15, 2024

Eli Lilly said on Friday the U.S. Food and Drug Administration approved its eczema drug for use in adults and children above 12 years old. The drug, which is an injectable medicine and branded Ebglyss, will be available in the next few weeks, the company said. Eczema, also known as atopic dermatitis, is an inflammatory skin condition that can cause itching, rashes and dry patches.

104

104

Pharmaceutical Technology

SEPTEMBER 15, 2024

GlobalData forecasts predict Enhertu will retain its dominant market position in the ADC treatment landscape.

98

98

FDA Law Blog: Biosimilars

SEPTEMBER 15, 2024

By Kurt R. Karst — “Inter Partes Review” and “Section 101” are not terms you typically run into on this all-things-FDA blog, but we have talked about such patent-related issues before ( here and here ), and they are important legal (patent) principles, particularly in the context of drug and biological products (and the Hatch-Waxman Amendments and the Biologics Price Competition and Innovation Act (“BPCIA”)).

Biosimilars 76

Biosimilars Drug Pricing 76

The Happy PharmD

SEPTEMBER 15, 2024

Retail pharmacy careers have long been a hot topic among pharmacists, and for good reason. These roles make up nearly half of all pharmacy jobs in the U.S., operating within a network of thousands of pharmacies across the country. Despite the sheer volume of prescriptions processed — over 4 billion annually — the landscape of retail pharmacy has undergone significant scrutiny in recent years.

Independent Pharmacies 52

Independent Pharmacies 52

Advertisement

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

PharmaTech

SEPTEMBER 15, 2024

Webinar Date/Time: Fri, Sep 27, 2024 11:00 AM EDT

52

52

The Happy PharmD

SEPTEMBER 15, 2024

Retail pharmacy careers have long been a hot topic among pharmacists, and for good reason. These roles make up nearly half of all pharmacy jobs in the U.S., operating within a network of thousands of pharmacies across the country. Despite the sheer volume of prescriptions processed — over 4 billion annually — the landscape of retail pharmacy has undergone significant scrutiny in recent years.

Independent Pharmacies 52

Independent Pharmacies 52

Pharmacy Joe

SEPTEMBER 15, 2024

In this episode, I’ll discuss a recent practice guideline on ketamine use for analgosedation in critically ill patients. Episode 957: Not every professional critical care society is high on ketamine for analgosedation Subscribe on iTunes , Android , or Stitcher The 2018 PADIS Guidelines published by the Society of Critical Care Medicine gave a positive recommendation for the use of ketamine saying: We suggest using low-dose ketamine (0.5 mg/kg IVP x 1 followed by 1-2 μg/kg/min infusion) as an ad

Inpatient 52

Inpatient Hospitals 52

The Happy PharmD

SEPTEMBER 15, 2024

Wondering how our healthcare professionals, especially pharmacists, are faring lately? Well, now’s the perfect time to dive into a discussion with me about the latest insights from the 2023 report by the Well-Being Index. Whether you’re new here or a regular viewer, a warm welcome awaits you! And if you’re eager to stay updated with insightful content, don’t forget to hit that subscribe button and notification bell.

Insurance Coverage and Processing 52

Insurance Coverage and Processing Dosage Documentation Communication 52

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

Pharmaceutical Technology

SEPTEMBER 15, 2024

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC treatment paradigm.

52

52

Pharmacy Times

SEPTEMBER 15, 2024

Overall survival results from the phase 3 KEYNOTE-522 study provide evidence of improved long-term outcomes from this pembrolizumab-based regimen.

Chemotherapy 44

Chemotherapy 44

Pharmacy Times

SEPTEMBER 15, 2024

Clinical research presented at ESMO 2024 highlights the significant survival benefits of perioperative and neoadjuvant immunotherapy with nivolumab and nivolumab plus ipilimumab, while emphasizing the role of biomarkers such as ctDNA and KRAS mutations in guiding treatment decisions.

29

29